Which medications in the drug class Antidiabetics, SGLT2 Inhibitors are used in the treatment of Metabolic Syndrome?

Updated: Mar 30, 2020
  • Author: Stanley S Wang, JD, MD, MPH; Chief Editor: Yasmine S Ali, MD, FACC, FACP, MSCI  more...
  • Print
Answer

Antidiabetics, SGLT2 Inhibitors

These agents lower the renal glucose threshold.

Canagliflozin (Invokana)

Canagliflozin is a selective sodium-glucose transporter-2 (SGLT2) inhibitor. SGLT-2 inhibition lowers the renal glucose threshold (ie, the plasma glucose concentration that exceeds the maximum glucose reabsorption capacity of the kidney); lowering the renal glucose threshold results in increased urinary glucose excretion. Indicated as an adjunct to diet and exercise, canagliflozin therapy is aimed at improving glycemic control in adults with type 2 diabetes. Also, it is indicated to reduce the risk of end-stage renal disease (ESRD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300 mg/day.

Empagliflozin (Jardiance)

Empagliflozin, an SGLT2 inhibitor, decreases blood glucose by increasing urinary glucose excretion. SGLT-2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose.

Indicated as an adjunct to diet and exercise, empagliflozin therapy is aimed at improving glycemic control in adults with type 2 diabetes. It is also indicated for lowering the cardiovascular death risk in adults with type 2 diabetes and cardiovascular disease.

Dapagliflozin (Farxiga)

Dapagliflozin reduces glucose reabsorption in the proximal renal tubules and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion. It is indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM). It is indicated as monotherapy, as initial therapy with metformin, or as an add-on to other oral glucose-lowering agents, including metformin, pioglitazone, glimepiride, sitagliptin, and insulin. It is also indicated to reduce hospitalization risk for heart failure in adults with T2DM and established cardiovascular disease (CVD) or multiple CV risk factors. 


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!